Please select the option that best describes you:
Topics:
Gastrointestinal Cancers • Gastric Cancer • Esophageal Cancer • Medical Oncology • Immunotherapy • Biologic Therapy/Immunobiology
Do you routinely obtain CPS assay to assess candidacy for chemoimmunotherapy in newly diagnosed metastatic esophageal/GEJ/gastric adenocarcinoma?
Is it necessary to test CPS given the FDA approvals are not contingent on CPS %?
If you do test, do you check 28-8 (nivolumab), 22C3 (pembrolizumab), or both? Are you testing everyone at diagnosis?
If you don't test, what is your preferred treatment approach?
Answer from: Medical Oncologist at Academic Institution
I am still apt to assess tumor PD-L1 CPS to help inform long-term benefit from first-line chemoimmunotherapy in a patient with metastatic disease. Intrapatient, interlesional heterogeneity for PD-L1 CPS has also been recognized in the literature corresponding to discordance in levels of PD-L1 CPS po...
Sign in or Register to read more
Answer from: Medical Oncologist at Community Practice
Even though FDA approval is not contingent on CPS score, it would still be a good idea to test for it. I test all patients at diagnosis of metastatic disease, and use assay 28-8 for nivolumab, as I intend to use nivolumab and chemotherapy as my preferred treatment approach.
Comments
Medical Oncologist at Alvin & Lois Lapidus Cancer Institute Northwest Hospital
Can you expand on your response? When you say, "it...
Can you expand on your response? When you say, "it...
Medical Oncologist at St Jude Heritage Medical Group
Very good follow up question since testing should ...
Very good follow up question since testing should ...